SCHEMBL24310682

SCHEMBL24310682

Cc1ccccc1Oc1nc(NS(=O)(=O)c2cccc(N)c2)nc(-c2ccccc2C(C)C)c1C(C)C

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 2/20 0.37
▸ SMN1; SMN2 Q16637 4/20 0.37
▸ PIK3C2B O00750 1/20 0.36
▸ PIK3C2G O75747 1/20 0.36
▸ KDM1A O60341 1/20 0.35
▸ TSHR P16473 2/20 0.35
▸ PRMT1 Q99873 1/20 0.34
▸ SCN9A Q15858 1/20 0.34
▸ ALDH1A1 P00352 3/20 0.34
▸ CYP19A1 P11511 1/20 0.34
▸ CYP3A4 P08684 1/20 0.34
▸ TDP1 Q9NUW8 1/20 0.34
▸ MAPK1 P28482 1/20 0.34
▸ PKM P14618 2/20 0.33
▸ GAA P10253 2/20 0.33
▸ LMNA P02545 1/20 0.33
▸ THRB P10828 1/20 0.33
▸ HTT P42858 1/20 0.33
▸ HSD17B10 Q99714 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29566908 1.00 POLB (0.37) POLBSMN1; SMN2PIK3C2BPIK3C2GKDM1A
SCHEMBL29566992 0.94 POLB (0.39) POLBSMN1; SMN2PIK3C2BPIK3C2GKDM1A
SCHEMBL24309374 0.94 POLB (0.39) POLBSMN1; SMN2PIK3C2BPIK3C2GKDM1A
SCHEMBL29567242 0.89 POLB (0.41) POLBPIK3C2BPIK3C2GTSHRPRMT1
SCHEMBL26651221 0.89 POLB (0.41) POLBPIK3C2BPIK3C2GTSHRPRMT1
SCHEMBL29567037 0.82 POLB (0.42) POLBSMN1; SMN2PIK3C2BPIK3C2GKDM1A
SCHEMBL24310681 0.82 POLB (0.42) POLBSMN1; SMN2PIK3C2BPIK3C2GKDM1A
SCHEMBL24309371 0.82 HTR1A (0.44) SCN9AMAPK1THRB
SCHEMBL29566727 0.82 HTR1A (0.44) SCN9AMAPK1THRB
SCHEMBL24310683 0.80 DHFR (0.31) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS, SAN DIEGO 2023-11-23 — — US disclosed
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS, SAN DIEGO 2023-11-23 — — US disclosed
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS, SAN DIEGO 2023-11-23 — — US disclosed
WO-2022076627-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS INCORPORATED (US) 2022-04-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR CFTR, SCNN1G, SCNN1B POLB 3593/4885SMN1; SMN2 4847/4885PIK3C2B 782/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback